BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17123800)

  • 1. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
    Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
    J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
    Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
    Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
    Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate.
    Zhang H; Wang ZY; Gong W; Li ZP; Mei XG; Lv WL
    Int J Pharm; 2011 Jul; 414(1-2):56-62. PubMed ID: 21596128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ; Liu ZJ; Shimoi K; Zhu BT
    Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique.
    Li Y; Jin W; Yan H; Liu H; Wang C
    Int J Pharm; 2013 Sep; 454(1):472-7. PubMed ID: 23806812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
    Marimpietri D; Brignole C; Nico B; Pastorino F; Pezzolo A; Piccardi F; Cilli M; Di Paolo D; Pagnan G; Longo L; Perri P; Ribatti D; Ponzoni M
    Clin Cancer Res; 2007 Jul; 13(13):3977-88. PubMed ID: 17606732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
    Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
    Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment.
    Wong MY; Chiu GN
    Anticancer Drugs; 2010 Apr; 21(4):401-10. PubMed ID: 20110806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
    Zhigaltsev IV; Maurer N; Akhong QF; Leone R; Leng E; Wang J; Semple SC; Cullis PR
    J Control Release; 2005 May; 104(1):103-11. PubMed ID: 15866338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
    Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
    J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC; Sharma A; Robertson GP; Kester M
    Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles.
    Fu JY; Blatchford DR; Tetley L; Dufès C
    J Control Release; 2009 Dec; 140(2):95-9. PubMed ID: 19709637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.